Reading time: 11 minutes
Digestive endoscopy is one of the highest-volume clinical activities in China, and leading endoscopy centres — Zhongshan Hospital of Fudan University, Beijing Friendship Hospital, Shanghai Changhai Hospital, and West China Hospital among others — operate at very high annual procedure volumes. This volume has supported a leading position in endoscopic detection and resection of early gastric, oesophageal, and colorectal cancer (ESD / EMR) [1]. China also carries one of the world’s largest chronic hepatitis B burdens, and its hepatology centres have extensive experience in chronic viral hepatitis, fatty liver disease (NAFLD / MASH), cirrhosis, and early hepatocellular carcinoma (HCC) management. This article works through what GI and hepatology problems are reasonable to address in China, the endoscopic and hepatologic options available, typical costs, and home-country handoff.
1. When Cross-Border Endoscopy or Hepatology Care Makes Sense
- Early cancer screening — a single high-quality stop for gastric, oesophageal, and colorectal cancer screening in high-risk individuals
- Surveillance plus endoscopic resection (ESD / EMR) for early-stage gastric, oesophageal, or colorectal neoplasia, avoiding open surgery
- Complex therapeutic endoscopy — ERCP for biliary or pancreatic disease, endoscopic ultrasound (EUS) with FNA, submucosal tumour resection (STER)
- Unexplained GI symptoms with inconclusive workup at home
- Chronic hepatitis management when home-country treatment is not progressing
- Early hepatocellular carcinoma — for radiofrequency or microwave ablation, surgical resection, or transplant evaluation
2. Why China’s Endoscopy Capability Is Strong
- Case volume: China carries one of the world’s highest gastric cancer burdens, and leading centres accumulate substantial early-cancer detection and ESD experience
- Equipment: Olympus EVIS X1, Fujifilm ELUXEO, magnification endoscopy with NBI / BLI, and chromoendoscopy are standard at top centres
- Programmatic depth: leading endoscopy units have well-established ESD, POEM, and EUS programmes
Typical endoscopic procedures:
| Procedure | Indication | Duration |
|---|---|---|
| Standard gastroscopy with NBI | Early cancer screening | 10–20 minutes |
| Chromoendoscopy + magnification + biopsy | Targeted high-risk lesion characterisation | 20–40 minutes |
| EMR (endoscopic mucosal resection) | Small lesions | 30–60 minutes |
| ESD (endoscopic submucosal dissection) | Medium-sized early-stage lesions | 60–180 minutes |
| POEM (peroral endoscopic myotomy) | Achalasia | 60–120 minutes |
| STER (submucosal tunnel endoscopic resection) | Submucosal tumour under 4 cm | 60–180 minutes |
| ERCP + stone extraction / stent | Biliary or pancreatic disease | 30–90 minutes |
| EUS + FNA | Pancreatic or submucosal mass | 30–60 minutes |
3. ESD — Organ-Preserving Cure for Early Cancer
ESD allows complete resection of early-stage gastric, oesophageal, or colorectal cancers (confined to the mucosa or superficial submucosa, without lymph node involvement) without an abdominal incision.
Compared with open surgery:
- Five-year survival is comparable for early-stage lesions
- Organ integrity is preserved
- Inpatient stay 3–7 days (vs 7–14 days for open surgery)
- Cost is roughly one-third to one-half
ESD indications follow the established Japanese gastric / oesophageal / colorectal cancer guidelines [2], which leading Chinese centres apply rigorously.
4. Hepatology — Hepatitis B, Fatty Liver, and Early HCC
Chronic hepatitis B:
- Nucleos(t)ide analogues: entecavir, tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF), tenofovir amibufenamide (TMF, domestically developed and approved in China) — all first-line
- Pegylated interferon alfa for selected patients
- Drug development: newer agents including HBV capsid inhibitors and siRNA therapeutics are in clinical trials in China
Major Chinese centres for chronic hepatitis include Beijing Youan Hospital, Beijing Ditan Hospital, Shanghai Public Health Clinical Center, Shanghai Changhai Hospital Hepatology Center, and Southwest Hospital of Army Medical University (Chongqing).
Fatty liver (NAFLD / MASH):
- Standard management: weight loss plus glycaemic and lipid control
- Newer drug therapy: resmetirom has been approved in the US and is under evaluation in Chinese clinical settings
- Moderate-to-severe fibrosis: FibroScan or MRE for monitoring
Early hepatocellular carcinoma (HCC):
- Radiofrequency ablation (RFA) or microwave ablation (MWA) for locally curative treatment of small tumours
- Transarterial chemoembolisation (TACE)
- Surgical resection
- Liver transplant (separately covered in the oncology series)
- Systemic therapy: atezolizumab plus bevacizumab, and several PD-1 / VEGF combination regimens approved in China
5. Hospitals to Consider
Digestive endoscopy:
| Hospital | City |
|---|---|
| Zhongshan Hospital of Fudan University, Endoscopy Centre | Shanghai |
| Beijing Friendship Hospital, Digestive Disease Centre | Beijing |
| Shanghai Changhai Hospital, Digestive Endoscopy Centre | Shanghai |
| West China Hospital, Gastroenterology | Chengdu |
| Sixth Affiliated Hospital of Sun Yat-sen University, Gastroenterology | Guangzhou |
| Second Affiliated Hospital of Zhejiang University, Gastroenterology | Hangzhou |
| Peking Union Medical College Hospital, Gastroenterology | Beijing |
Hepatology:
| Hospital | City |
|---|---|
| Beijing Youan Hospital | Beijing |
| Beijing Ditan Hospital | Beijing |
| Shanghai Public Health Clinical Center | Shanghai |
| Southwest Hospital of Army Medical University, National Infectious Disease Centre | Chongqing |
| First Affiliated Hospital of Zhejiang University School of Medicine, Infectious Diseases | Hangzhou |
| Huashan Hospital of Fudan University, Infectious Diseases | Shanghai |
6. Typical Process
Early cancer screening package (3–5 days):
- Day 1: gastroscopy plus colonoscopy with chromoendoscopy / magnification and biopsy as needed
- Days 2–3: pathology results
- Days 4–5: schedule ESD or EMR if needed
ESD treatment (5–7 days):
- Days 1–2: preoperative evaluation
- Day 3: ESD
- Days 4–6: observation and discharge
- Day 7: review
Comprehensive hepatology evaluation (5–7 days):
- Days 1–3: full hepatologic assessment (viral load, liver function, AFP, FibroScan, upper abdominal MRI)
- Days 4–5: treatment plan and drug initiation
- Days 6–7: observation and education
7. Typical Costs (USD, 1 USD = 6.5 RMB)
| Item | Public tertiary international dept. | High-end private |
|---|---|---|
| Early cancer endoscopy screening package (with biopsy) | 600–1,200 | 1,000–2,200 |
| Single gastroscopy / colonoscopy with NBI and magnification | 200–500 | 400–800 |
| EMR (small lesion) | 500–1,500 | 800–2,500 |
| ESD (medium lesion) | 2,500–5,500 | 4,500–9,000 |
| POEM | 4,000–7,500 | 7,000–12,000 |
| ERCP + stone extraction or stent | 2,000–4,500 | 3,500–7,500 |
| Comprehensive chronic hepatitis B evaluation | 600–1,500 | 1,000–2,500 |
| Entecavir / TAF monthly | 30–80 | 50–120 |
| HCC RFA (single session) | 3,500–6,500 | 5,500–10,000 |
| TACE (single session) | 2,500–5,500 | 4,500–9,000 |
US reference:
- ESD typically USD 12,000–25,000 [3]
- ERCP USD 5,000–12,000
8. Handing Care Back Home
- Hepatitis B nucleos(t)ide therapy: widely available globally; doses and brands can transition smoothly
- After ESD: home-country gastroenterology follow-up endoscopy at 6 and 12 months
- HCC surveillance: AFP plus liver imaging every 3 months
9. What MedCareInChina Can and Cannot Do on the GI and Hepatology Pathway
Our two products are Remote Consultation and In-China Accompanied Care.
- Remote Consultation: a USD 800 single-expert consultation with a GI or hepatology specialist who reviews your records and gives an initial plan
- In-China Accompanied Care: hospital accompaniment with translation through endoscopic procedures, ESD or surgery, and hepatologic evaluation
What we do not do: long-term liver disease follow-up, remote endoscopy reading.
10. Action Checklist
- Bring upper GI endoscopy, colonoscopy, pathology, liver evaluation, and imaging from the last 12 months
- Engage a remote consultation to determine whether ESD or further evaluation is needed
- Apply for an S2 visa
- Plan 3–7 days for screening, 5–10 days for treatment
- Continue scheduled follow-up at home after returning
Sources
[1] Chinese Society of Digestive Endoscopy — Annual reports and clinical guidance [2] Japan Gastroenterological Endoscopy Society — ESD / EMR guidelines [3] American Society for Gastrointestinal Endoscopy — Procedure cost references: https://www.asge.org/ [4] WHO — Global Hepatitis Report: https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/hepatitis [5] National Medical Products Administration of China — Approval records for nucleos(t)ide analogues and HCC systemic therapies: https://www.nmpa.gov.cn/
